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Abstract
Background: Data regarding the most efficacious and least toxic schedules for the use of colistin are scarce. The
aim of this study was to determine the incidence and the potential risk factors of colistin-associated nephrotoxicity
including colistin plasma levels.
Methods: A prospective observational cohort study was conducted for over one year in patients receiving
intravenous colistin methanesulfonate sodium (CMS). Blood samples for colistin plasma levels were collected
immediately before (Cmin) and 30 minutes after CMS infusion (Cmax). Renal function was assessed at baseline, on
day 7 and at the end of treatment (EOT). Severity of acute kidney injury (AKI) was defined by the RIFLE (risk, injury,
failure, loss, and end-stage kidney disease) criteria.
Results: One hundred and two patients met the inclusion criteria. AKI related to CMS treatment on day 7 and at
the end of treatment (EOT) was observed in 26 (25.5%) and 50 (49.0%) patients, respectively. At day 7, Cmin (OR, 4.63
[2.33-9.20]; P < 0.001) was the only independent predictor of AKI. At EOT, the Charlson score (OR 1.26 [1.01-1.57];
P = 0.036), Cmin (OR 2.14 [1.33-3.42]; P = 0.002), and concomitant treatment with ≥ 2 nephrotoxic drugs (OR 2.61
[1.0-6.8]; P = 0.049) were independent risk factors for AKI. When Cmin was evaluated as a categorical variable, the
breakpoints that better predicted AKI were 3.33 mg/L (P < 0.001) on day 7 and 2.42 mg/L (P < 0.001) at EOT.
Conclusions: When using the RIFLE criteria, colistin-related nephrotoxicity is observed in a high percentage of patients.
Cmin levels are predictive of AKI. Patients who receive intravenous colistin should be closely monitored and Cmin might
be a new useful tool to predict AKI.
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Background
Colistin is an old antibiotic that has been recently re-
introduced in clinical practice because of the increase in
the incidence of infections caused by multidrug resistant
Gram-negative bacteria (MDR-GNB) and the retained
antibacterial activity of colistin against MDR-GNB. How-
ever, data regarding its effectiveness and safety are scarce
and controversial. For this reason, there is interest in de-
termining the most effective and least toxic therapeutic
schedule.
Rates of nephrotoxicity in recent studies designed to
assess this outcome have ranged from 6% to 14% in
some and from 32% to 55% in others [1-4]. However,
despite the large number of publications, different
nephrotoxicity definitions, differences in dosing sched-
ules, and a lack of control of risk factors for nephrotox-
icity have complicated an understanding of the real
clinical relevance of this adverse effect [5]. Furthermore,
the nephrotoxicity of colistin has been assessed mainly
in retrospective studies [6,7] that made it difficult to
draw conclusions.
Risk factors for nephrotoxicity found in different stud-
ies included older age, pre-existing renal insufficiency,
hypoalbuminemia, and concomitant use of non-steroidal
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anti-inflammatory drugs (NSAIDs) or vancomycin [4].
Furthermore, some studies [7-11] have suggested that
colistin-associated nephrotoxicity is related to the total
cumulative dose and duration of therapy, whereas other
studies have not shown this association [1,12]. However,
the possible relationship between colistin plasma con-
centration and nephrotoxicity has not been previously
assessed.
The aim of this study was to determine the incidence
of and the risk factors for colistin-associated nephro-
toxicity by using the RIFLE (risk, injury, failure, loss,
and end-stage kidney disease) criteria and assessing
the relationship between colistin plasma levels and
nephrotoxicity.
Methods
This prospective observational study was performed at a
400-bed acute-care university hospital in Barcelona,
Spain. A pharmacy-generated alarm system was used to
identify patients on CMS treatment for therapy of infec-
tions caused by MDR-GNB. From January 2010 to June
2011, patients (>18 years) were included if they had re-
ceived colistin methanesulfonate sodium (CMS) for at
least 4 days. Patients were excluded if they were receiv-
ing renal replacement therapy prior to the initiation of
CMS.
The ethical committee of the hospital (Comité Étic de
Investigació Clínica del Parc de Salut MAR) approved
the study. Informed consent was obtained from all par-
ticipating patients or their legal representatives.
CMS for injection was used and dosed in millions of
international units (IU) throughout the study. The drug
was administered intravenously in 100 mL normal
saline over 30 minutes in the commercially available
colistimethate formulation for injection (GES Genéricos
Españoles ®), with each vial containing 80 mg CMS
(equivalent to 1 million international units of CMS).
Dose selection was based on the individual criteria of
the responsible clinicians, who were not aware that this
study was being performed. Although there were some
dose adjustments based on baseline renal function, com-
mon colistin doses ranged from 1 to 3 million inter-
national units (IU) every 8 hours (3–9 million IU daily).
Dose adjustments were made according to the package
insert’s recommended dosing as follows: GFR ≥ 76 mL/
min/1.73 m2, 4–6 million IU daily in three doses; GFR
40 to 75 mL/min/1.73 m2, 2–3 million IU daily in 2
doses; GFR 25 to 40 mL/min/1.73 m2, 1.5-2 million IU
daily divided in 1 or 2 doses and; GFR < 25 mL/min/
1.73 m2 , 0.6-1 million of IU daily every 36 hours.
Serum creatinine level and estimated glomerular filtra-
tion rate (GFR) were recorded at baseline, on day 7 and
at the end of treatment (EOT). We chose these set
points because blood tests are done routinely for all
inpatients at least once a week and at the end of treat-
ment. The abbreviated Modification of Diet in the Renal
Disease Equation (MDRD-4) [13] was used to calculate
GFR. Chronic kidney disease (CKD) at baseline was con-
sidered if GFR was < 60 mL/min/1.73 m2 for ≥ 3
months. Patients with increased creatinine (> 1.4 mg/dL)
or GFR < 90 mL/min/1.73 m2 at admission and no prior
data regarding chronicity were considered as having
acute renal failure due to any cause. The RIFLE criteria
(risk, injury, failure, loss, and end-stage kidney disease),
estimated with exclusion of the urinary output criterion,
were used for detection and stratification of AKI [14]
(Table 1). AKI during CMS treatment was defined as a
1.5-fold or more increase in serum creatinine and/or a
decrease in the GFR of 25% or more. These criteria
needed to be fulfilled for at least 2 consecutive determi-
nations 24 hours apart, after ≥ 4 days of CMS therapy.
Patients who developed AKI were followed up for a
period of 30 days after the end of CMS treatment to
evaluate the reversibility of this toxicity. Patients who
died or had no data during this period were excluded
from this analysis.
Data on demographic characteristics including age,
gender, body weight, size, and body mass index were
collected. Data on the indication for CMS, the adminis-
tration schedule, the daily CMS dose recorded as mil-
lions of IU, the total cumulative CMS dose (millions of
IU), and the duration of treatment were collected.
Other data recorded included the presence of CKD at
baseline, the Charlson score [15], the severity of disease
at the time of the first CMS dose stratified according to
the Acute Physiology and the Chronic Health Evalu-
ation (APACHE) II [16]. The concomitant use of
aminoglycosides, vancomycin, angiotensin II receptor
blockers, angiotensin-converting enzyme inhibitors, loop
diuretics, intravenous dye, amphotericin B, non-steroidal
anti-inflammatory drugs (NSAIDs), the need for vasopres-
sor drugs, and discontinuation of CMS treatment because
of AKI were also recorded. The patient’s clinical status at
the beginning of CMS treatment was defined as infection,
Table 1 Definition of the RIFLE criteria to assess AKI
Category criteria Definition
Risk (R) Increased creatinine level × 1.5
or GFR decrease > 25%
Injury (I) Increased creatinine level × 2 or GFR
decrease > 50%
Failure (F) Increased creatinine level × 3, GFR decrease
> 75%, or creatinine level > 4 mg/dL
Loss (L) Persistent acute renal failure or loss of
function for > 4 weeks
End-Stage Kidney Disease
(ESKD) (E)
ESKD for > 3 months
*GFR, glomerular filtration rate.
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severe sepsis and shock, according to the standard defin-
ition [17]. Clinical response was defined as the resolution
of signs, symptoms, and laboratory parameters that
defined infection for each patient. The 30-day all-
cause mortality was also recorded.
Evaluation of the colistin concentration in plasma was
performed after 3 days of treatment, when the colistin
concentrations had reached steady state. The samples
were immediately centrifuged (3000 g for 10 minutes)
and the plasma was stored at −80°C until analysis. Colis-
tin plasma trough concentrations (Cmin) were measured
just before the next dose. Maximum plasma concentra-
tions (Cmax) were taken 30 minutes after the end of the
CMS infusion (1 h after the start of infusion).
Colistin concentrations in plasma were determined
using a validated high-performance liquid chromatog-
raphy (HPLC) method as described by Li et al. [18], with
minor modifications. After protein precipitation, the
samples were centrifuged (14000 g, 5 min) and the
supernatant transferred to solid phase extraction (SPE)
C18 cartridges (Sep-Pak, Waters, Milford, MA, USA), in
which derivation with 9-fluorenylmethyl chloroformate
(FMOC-Cl) was performed. Elution of the fluorescence
derivatives was performed with acetone mixed with
acetonitrile and boric acid. Finally, 20 μl of the mixture
was injected into the HPLC. The HPLC system was
made up of Waters equipment that included a Waters
2475 multi-λ Fluorescence Detector, a Waters 1525 bin-
ary pump with column heater, a Waters degasser, and a
Waters 717 autoinjector sampler. The stationary phase
was a Waters SunFire column C18, 4.6 × 15.0 mm, 5
μm. The mobile phase was a mixture of acetonitrile,
tetrahydrofuran and water delivered at an isocratic flux
of 1 mL/min. The chromatogram run time was 20 mi-
nutes and the detector setting was excitation wavelength
260 nm and emission wavelength 315 nm. The concen-
trations of colistin were calculated by multiplying the
obtained colistin sulfate plasma concentrations by 1163/
1403 (1163 being the average molecular weight of colis-
tin A and B, which are the greater part of the products,
and 1403 the average molecular weight of colistin sul-
fate). The colistin plasma concentration in each patient
was calculated as the sum of colistin A and B, the two
main components. Calibration curves were linear in the
range 0.1-8 mcg/ml and the accuracy quality control
samples varied from 90–110 % of the nominal concen-
tration for intraday and interday analysis, with a preci-
sion (CV%) of 10% or less. The limit of quantification
was 0.1 mcg/ml and the limit of detection was 0.05 mcg/
mL.
Statistical analysis
Dichotomous data were compared using a χ2 or Fisher
exact test. Normally distributed continuous data are
expressed as means with standard deviations (SD) and
were compared using the t-test. Otherwise, values are
presented as means with interquartile range (IQR) and
were compared using the Mann–Whitney U-test.
Multivariate analysis of risk factors for colistin nephro-
toxicity was constructed by using logistic regression.
Univariate analyses were performed separately for each
of the risk factor variables to ascertain the odds ratio
and 95% confidence interval (CI). All clinically import-
ant covariates and those with a P value < 0.2 in the
univariate analyses were included in the multivariate
analysis. Since Cmax and Cmin values were almost equal,
only one of these variables was included in the model.
Following Couet et al. [19], Cmin was chosen because it
is more convenient from a practical viewpoint and be-
cause CMS would then be minimal and the risk of
colistin concentration overestimation resulting from
post-sampling CMS hydrolysis would therefore be con-
siderably reduced.
As we had found a relationship between the develop-
ment of AKI on day 7 and at the EOT and between co-
listin levels and 30-day all-cause mortality, a multivariate
analysis of risk factors for 30-day all-cause mortality was
performed using a logistic regression.
Multivariate logistic regression models were assessed
with the Hosmer–Lemeshow goodness-of-fit test and
the C-statistic representing the area under the receiver
operating characteristics (ROC) curve (AUC).
The ROC curve was used to identify a categorical
breakpoint for Cmin that would better identify patients
who develop acute kidney injury (AKI) on day 7 and at
the end of treatment. For all analyses, a two-sided P
value < 0.05 was considered to be statistically significant.
The Statistical Package for the Social Sciences (SPSS,
version 15.0) was used for statistical analysis.
Results
During the study period, colistin was prescribed to 119
patients, 9 of whom did not complete the study proto-
col, 5 of whom received colistin treatment for less than
72 hours, and 3 of whom were on hemodialysis. The
study population included 102 patients. Patient charac-
teristics are summarized in Table 2.
Colistin was administered at 1 million IU three times
daily in 28 (27.4%) patients, at 2 million IU three times
daily in 42 (41.2%) patients, at 3 million IU three times
daily in 16 (15.7%) patients, and at other doses adjusted
by renal function in 16 (15.7%) patients. Table 3 shows
the characteristics of patients receiving different CMS
dosage regimens.
AKI was detected in 53 (51.9%) patients at any time
during treatment (26 on day 7, and 50 at the EOT).
Table 4 shows the distribution of AKI on day 7 and at
the EOT on the basis of the RIFLE criteria. Fourteen out
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of 53 (26.4%) patients who developed AKI during treat-
ment underwent a CMS dose reduction and 3 (5.6%) had
to stop treatment because of AKI. None of the patients
who developed AKI needed renal replacement therapy.
Patients had received CMS 10.8 ± 6.2 (SD) days when
dose adjustment was done. Dose modification was done
within the first week in 3 (21.4%) patients and after this
time in 11 (78.6%).
Adjustments of CMS dose were done by prolonging
the dosing interval in 7 (50%) patients, by reducing the
single dose in 4 (28.6%) patients, and by combining both
strategies in 3 (21.4%) of patients. CMS dose adjustment
at any time was associated with recovery of baseline
renal function at the EOT (P = 0.016). However, neither
time until dose adjustment nor strategy of dosing modi-
fication was related to recovery of baseline renal func-
tion at the EOT (data not shown).
At the end of follow up, 33 out of 53 (62.3%) had re-
covered their baseline renal function, 16 (30.2%) died be-
fore recovery of renal function, and 4 (5.7%) had no
available data. No differences were observed in terms of
mean time until recovery of baseline renal function be-
tween patients with and without CMS adjustment (10 ±
10.9 vs 10 ± 12.5, respectively; P = 0.6).
The univariate analyses used to identify risk factors for
AKI on day 7 and at EOT are shown in Table 5. Patients
with AKI on day 7 were older, had a higher Charlson
score, had received higher CMS cumulative doses (from
baseline until day 7), and had lower plasma albumin
levels. In addition, Cmax and Cmin were higher than in
those without AKI. At the EOT, variables related to AKI
were age, Charlson score, CMS cumulative dose and
duration of treatment, low plasma albumin levels, con-
comitant treatment with NSAIDs and loop diuretics,
and colistin plasma levels (Cmax and Cmin). Another
finding to consider is the fact that patients with acute
renal failure at baseline achieved higher trough and peak
colistin plasma levels (0.86 [0.11-5.99] vs 1.79 [0.56-5]
and 1.00 [0.15-6.62] vs 1.82 [0.52-5]; P = 0.025 and P =
0.017, respectively). In spite of this, the presence of acute
renal failure was not related to the development of AKI
either on day 7 or at the EOT.
Variables with a p value ≤ 0.20 were introduced in a
multivariate logistic regression model. For day 7, Cmin
(odds ratio [OR] 4.7; 95% confidence interval [CI] 2.38-
9.29) was the only predictor of renal dysfunction. For
EOT, Charlson score (OR 1.3; 95% CI 1.015-1.572),
Cmin (OR 2.1; 95% CI 1.33-3.42), and co administration
of ≥ 2 nephrotoxic drugs (OR 2.61; CI 95% 1.0-6.7)
were identified as risk factors for AKI (Table 6). The
final model showed a very good overall discriminatory
power for AKI with an AUC value of 0.898 (95% CI
0.82-0.97, P < 0.001) on day 7 and 0.772 (95% CI 0.68–
0.86, P < 0.001) at the EOT.
Table 2 Patient characteristics
Included patients
(n=102)
Age, years* 69 (24–91)
Male sex, n (%) 79 (77.5)
APACHE II** 12.4 ± 5.68
Clinical status, n (%):
- Severe sepsis 48 (47.1)
- Shock 8 (7.8)
Intensive Care Unit admission, n (%) 24 (23.5)
Type of infection, n (%)
- Pneumonia 24 (23.5)
- Acute bronchitis 23 (22.5)
- Urinary tract infection 15 (14.7)
- Skin and soft tissue infection and surgical
site infection
15 (14.7)
- Bacteremia 5 (4.9)
- Others 20 (19.6)
Type of CMS treatment, n (%)
- Empirical 3 (2.9)
- Directed: 99 (97.1)
- Pseudomonas aeruginosa 89 (89.9)
- Acinetobacter baumannii 9 (9.1)
- Klebsiella pneumoniae 1 (1)
1CMS daily dose (millions IU)** 5.21 ± 2.24
1CMS total dose, (MU)** 100.54 ± 92.8
1CMS duration, days** 19.57 ± 15.4
2GFR at baseline (ml/min/1.73 m2)* 127.9 (22.3-560)
Patients with 3CKD at baseline, n (%) 23 (22.5)
4Cmin (mg/mL)* 1.06 (0.11-5.99)
5Cmax (mg/mL)* 1.11 (0.15-6.62)
Patients with nephrotoxicity at day 7, n (%) 26 (25.5)
- R (Risk) 16 (61.5)
- I (Injury) 8 (30.7)
- F (Failure) 2 (7.6)
Patients with nephrotoxicity at the end of
treatment, n (%)
50 (49)
- R (Risk) 13 (26)
- I (Injury) 23(46)
- F (Failure) 14 (28)
Clinical response, n (%) 79 (77.5)
Data are n (%) except where indicated.
* Median (interquartile range).
** Mean ± SD.
1CMS:colistinmethanesulfonate sodium. 2GFR: Glomerular filtration rate. 3CKD:
chronic kidney disease. 4Cmin: colistin trough plasma concentrations at steady
state. 5Cmax: colistin maximum plasma concentrations at steady state.
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When Cmin was evaluated as a categorical variable,
based on the ROC curve, the breakpoints that best pre-
dicted AKI at day 7 and at the EOT were 3.33 mg/L and
2.42 mg/L with a sensitivity of 0.46 and 0.42 and specifi-
city of 1.00 and 0.96, respectively (P < 0.001). The posi-
tive predictive values and the negative predictive values
were 100% and 87.5% and 84.4% and 62.8%, respectively.
Cmin was also evaluated by defining four groups on the
basis of quartiles as shown in Table 7. Both AKI on day
7 and at the EOT were related to Cmin (p < 0.001).
The 30-day all-cause mortality rate was 32.4%. Another
important finding is that in the univariate analysis the de-
velopment of AKI on day 7 and at the EOT were both
related to 30-day all-cause mortality (p = 0.031 and p =
0.006, respectively). Furthermore, higher Cmin values were
also related to 30-day mortality (p = 0.010) (data not
shown). However in the multivariate analysis the only fac-
tors related to 30-day all-cause mortality were AKI at the
EOT (OR 4.01; 95% CI 1.57-10.23; P = 0.004) and APA-
CHE score (OR 1.11; 95% CI 1.09-1.21; P = 0.008).
Discussion
The aim of this study was to determine the incidence of
colistin-associated nephrotoxicity and evaluate the colis-
tin plasma concentrations as a predictor of AKI in pa-
tients treated with this antimicrobial agent. Using the
RIFLE criteria to assess the incidence of AKI related to
CMS treatment on day 7 and at the EOT, nephrotoxicity
was observed in 25% and 49% patients respectively.
The reported rate of colistin-associated nephrotoxicity
varies from 0% to 37% in older studies [2,3,20,21]. This
variability could be the result of differences in the defini-
tions of nephrotoxicity and in the dose and duration of
treatment with CMS in earlier studies. In the present
study, the rates of AKI at EOT (49%) are slightly higher
than those reported in recent studies that used the RI-
FLE criteria (43-45%) [8,9].
The association between increased colistin dose and
improved outcome has been previously reported by
Table 3 Clinical and demographic characteristics of patients receiving different CMS dosage regimens
Variable Colistin dosage regimen, n (%) P
1 million IU/8 h
(n = 28)
2 million IU/8 h
(n = 42)




Age (yrs) 74 (24–85) 67 (27–91) 55.5 (28–74) 73 (42–85) 0.023
Nº (%) of male patients 22 (78.6) 32 (76.2) 14 (87.5) 11 (68.8) 0.64
Charlson score 4.8 ± 2.8 4.36 ± 2.6 3.7 ± 2.5 4.8 ± 2.1 0.41
Nº (%) of severe sepsis 11 (39.3) 22 (52.4) 9 (56.3) 6 (37.5) 0.5
Nº (%) septic shock 1 (3.6) 3 (7.1) 2 (12.5) 2 (12.5) 0.63
APACHE II 12.8 ± 6.7 11.9 ± 4.6 11.5 ± 4.45 13.7 ± 7.5 0.28
1CKD at baseline 12 (42.9) 7 (16.7) 1 (6.3) 11 (68.8) <0.0001
Colistin dose (in 2CBA) in mg/kg/day (3IBW) 1.48 ± 0.3 2.9 ± 0.37 4.38 ± 0.9 1.54 ± 0.82 <0.0001
4Cmin 0.71 (0.2-2.01) 1.14 (0.11-5) 1.84 (0.45-5.99) 1.5 (0.16-3.02) 0.003
5Cmax 0.65 (0.24-1.99) 1.13 (0.15-5) 1.84 (0.5-6.62) 1.5 (0.16-3.7) 0.001
6CMS cumulative dose 58.5 ± 50.6 111.7 ± 85.9 171.5 ± 105.7 73.9 ± 111.3 <0.0001
CMS duration treatment 20 ± 16.5 19.5 ± 15.6 19.25 ± 8 19.2 ± 19.8 0.41
Concomitant antibiotics 15 (53.6) 23 (54.8) 10 (62.5) 8 (50) 0.9
7AKI at day 7 5 (17.9) 11 (26.2) 7 (43.8) 3 (18.8) 0.25
AKI at 8EOT 14 (50) 21 (50) 9 (56.3) 6 (37.5) 0.7
Clinical response 25 (89.3) 32 (76.2) 11 (68.8) 11 (68.8) 0.3
Data are n (%) except where indicated.
* Median (interquartile range).
** Mean ± SD.
1CKD: chronic kidney disease. 2CBA: colistin base activity. 3IBW: ideal body weight. 4Cmin: colistin trough plasma concentrations at steady state.
5Cmax: colistin
maximum plasma concentrations at steady state. 6CMS: colistinmethanesulfonate sodium 7AKI: acute kidney injury. 8EOT: end of treatment.
Table 4 patient relationship to the RIFLE criteria on day 7
and at the EOT
Criterion N° (%) of patients fulfilling criterion
Day 7 (n = 102) EOT (n = 102)
No injury 76 (74.5) 52 (51)
Risk (R) 16 (15.7) 14 (13.7)
Injury (I) 8 (7.8) 23 (22.5)
Failure (F) 2 (2) 13 (12.7)
Loss (L) 0 (0) 0 (0)
ESKD (E) 0 (0) 0 (0)
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some authors [12,22]. In addition, recent PK and PD
studies have revealed a need for higher doses of colistin
to maximize efficacy [23,24]. By contrast, in this study,
higher doses of colistin were not related to a better clin-
ical outcome. However, clinical response rate was similar
to those reported by other authors [2,25-28]. These re-
sults could be explained in part by the fact that only 16
patients had received higher CMS doses (3 million IU
every 8 hours).
The finding that Cmin and Cmax values were practically
identical once the steady state was reached, has been
previously observed by other authors [24]. In this sce-
nario Couet et al. recommend not to try to differentiate
between peak and trough concentrations [19] and for
the purposes of drug monitoring, they say it would be
more advisable to sample immediately before CMS dos-
ing because CMS concentrations would then be minimal
and the risk of colistin concentration overestimation
resulting from post-sampling CMS hydrolysis would
therefore be considerably reduced.
The most important finding of our study is that Cmin
is a stronger predictor of AKI both on day 7 and at
EOT. In previous reports, some authors have demon-
strated that colistin nephrotoxicity is related to the
cumulative dose and the duration of CMS therapy
[7,9,11,26,27]. In the current study, the duration of
therapy and the cumulative CMS dose showed a trend
towards statistical significance in the univariate analysis
that disappeared after adjusting for other variables. In
addition, daily colistin dose calculated by analyzing the
amount of colistin base activity (CBA) per ideal body
weight (data not shown) was not related to AKI. These
results are consistent with those of Falagas et al. [28,29]
but in disagreement with Pogue et al. [8], who have
recently shown that renal insufficiency occurred in a
dose-dependent manner.
The association between higher doses of CMS and
higher colistin plasma concentrations suggest that this
polymyxin has linear pharmacokinetics. However, while
colistin levels were the strongest predictor of AKI, no















Age, years* 66.5 (24–91) 73 (41–84) 0.036 65 (24–91) 72.5 (30–87) 0.016
Male sex 61 (80.3) 18 (69.2) 0.281 40 (76.9) 39 (49.4) 1
Charlson Index* 4.12 ± 2.58 5.5 ± 2.34 0.031 3.6 ± 2.4 5.36 ± 2.3 0.001
APACHE II 14.9 ± 6.4 14.8 ± 7 0,32 15.3 ± 6 14.2 ± 7 0,16
Clinical status:
- Severe sepsis 39 (51.3) 9 (34.6) 0.175 24 (46.2) 24 (48) 1
- Shock 7 (9.2) 1 (3.8) 0.457 7 (13.5) 1 (2) 0.06
Acute renal failure at baseline 11 (14.5) 4 (15.4) 1 4 (7.7) 11 (22) 0.052
1CKD at baseline 17 (22.3) 6 (23) 1 11 (21.15) 12 (24) 0.81
Albumin* 2.8 ± 0.62 2.5 ± 0.62 0.047 2.8 ± 0.62 2.6 ± 0.62 0.031
1BMI (Kg/m2)* 25.6 ± 5.9 24.3 ± 5.03 0.26 25.2 ± 5 25.4 ± 6.35 0.75
3CMS total dose (MU)* 35.1 ± 15.15 42 ± 15.84 0.06 97.3 ± 106.35 103.9 ± 78.5 0.047
Duration of CMS treatment, days* 18.7 ± 16.6 21.02 ± 14.42 0.047
4Cmin, mg/mL* 0.78 (0.11-3.2) 3.11 (0.45-5.99) <0.0001 0.7 (0.11-5.7) 1.18 (0.16-5.99) <0.0001
5Cmax, mg/mL* 0.78 (0.15-3) 3.2 (0.68-6.62) <0.0001 0.74 (0.15-6.10) 1.81 (0.16-6.62) <0.0001
Concomitant aminoglycoside use 24 (31.6) 8 (30.8) 1 16 (30.8) 16 (32) 1
Concomitant vancomycin use 8 (10.5) 1 (3.8) 0.442 3 (5.8) 6 (12) 0.314
Concomitant 6NSAID use 11 (14.5) 4 (15.4) 1 3 (5.8) 12 (24) 0.012
Concomitant loop diuretic use 31 (40.8) 15 (57.7) 0.172 16 (30.8) 30 (60) 0.005
Other concomitant nephrotoxic drugs 17 (22.4) 4 (14.4) 0.579 13 (25) 8 (16) 0.33
≥ 2 nephrotoxic drugs 37 (48.7) 13 (50) 1 20 (38.5) 30 (60) 0.047
Data are n (%) except where indicated.
* Median (interquartile range).
** Mean ± SD.
1CKD: chronic kidney disease. 2BMI: body mass index. 3CMS:colistinmethanesulfonate sodium. 4Cmin: colistin trough plasma concentrations at steady state.
5Cmqx:
colistin maximum plasma concentrations at steady state. 6NSAID: non-steroidal anti-inflammatory drugs.
Sorlí et al. BMC Infectious Diseases 2013, 13:380 Page 6 of 9
http://www.biomedcentral.com/1471-2334/13/380
relationship was found between AKI and daily colistin
dose nor cumulative colistin dose. This could be because
the average colistin steady-state plasma concentrations
(both Cmax and Cmin) varied in a relatively wide range,
reflecting great inter-patient variability. In a population
pharmacokinetic study, Garonzik et al. [23] observed a
strong inverse trend between colistin steady-state plasma
concentrations (Css, avg) and creatinine clearance, sug-
gesting that in patients with normal or moderately im-
paired renal function, the currently recommended daily
doses of CMS are not sufficient to obtain efficacious
steady-state concentrations of colistin, and proposed a
maintenance dose equation for optimizing colistin efficacy.
However, according to Pogue et al. [8], the proposed doses
would significantly increase risk of AKI. In this scenario,
another group [19] have analyzed the effect of altered
CMS renal clearance on Css, avg and have concluded that
moderate renal impairment should not only be viewed as
a risk factor for toxicity due to overexposure, but also as
an opportunity to reach efficient colistin concentrations.
This relationship between creatinine clearance and colistin
plasma levels was also observed in our study, as patients
who had developed acute renal failure at baseline achieved
higher colistin plasma levels at steady state.
Regarding colistin plasma levels, another factor to con-
sider is that impaired enzymatic activity caused by liver
disease or drug–drug interactions could perhaps be re-
sponsible for reduced colistin clearance and, in turn,
high average steady-state concentrations [19]. Unfortu-
nately, all these data suggest that colistin clearance impair-
ment in a particular individual is almost impossible to
predict and that therefore colistin concentration monitor-
ing could help physicians to adapt CMS dosing regimens.
Another point of the study that needs to be underlined
is the fact that the co-administration of ≥ 2 nephrotoxins
during CMS treatment was associated with AKI at EOT.
This fact could be explained by the additive effect of
nephrotoxic drugs during treatment. Although some re-
cent reports suggest an association between vancomycin
and nephrotoxicity [30], in this study vancomycin was
not a risk factor for AKI. Furthermore, in line with
Pogue et al. [8], aminoglycosides were not related to
nephrotoxicity. These results could be influenced by the
limited sample size. In any case, it would be advisable
for physicians always to consider the potential synergis-
tic effect between colistin and other nephrotoxic drugs.
Regarding the relationship between the development
of AKI at the EOT and all cause 30-day mortality, other
authors have demonstrated that AKI itself is associated
with higher mortality [6,30].
In conclusion, these results emphasize that colistin is a
drug with a narrow therapeutic range because the find-
ings of possible better outcomes with optimized colistin
dosing should be tempered with the equal possibility of
worsening renal function associated with higher colistin
plasma levels. In line with this and also with Dalfino
et al. [26,27], our results suggest that the administration
of higher daily CMS doses while prolonging the dosing
interval (according to colistin’s concentration-dependent
pharmacokinetic behavior) could be a reasonable strat-
egy to maximize efficacy without increasing the risk of
nephrotoxicity.
Our study has some limitations. Despite the prospect-
ive design, the lack of a control group represents a major
limitation. We were not able to assess the potential rela-
tionship between values of the area under the colistin
concentration versus time curves over 24 h (AUC0-24)
and AKI, mainly because of the difficulty of taking
Table 6 Multivariate analysis for independent risk factors






Age 1.01 (0.95-1.08) 0.75
Charlson score 1.04 (0.71-1.52) 0.84
Albumin 0.89 (0.33-2.42) 0.83
1CMS cumulative dose at day 7 0.99 (0.94-1.04) 0.73





Age 0.98 (0.93-1.03) 0.51
Charlson score 1.3 (1.01-1.57) 0.036
Albumin 0.59 (0.25-1.38) 0.22
CMS cumulative dose 0.99 (0.98-1) 0.38
CMS duration treatment 1.03 (0.98-1.08) 0.24
Cmin 2.1 (1.33-3.42) 0.002
3NSAID use 5.09 (0.9-28.54) 0.64
Loop diuretic use 1.97 (0.61-6.38) 0.25
Co-administration of
> 2 nephrotoxic drugs
2.61 (1–6.7) 0.049
1CMS:colistinmethanesulfonate sodium. 2Cmin: colistin trough plasma
concentrations at steady state. 3NSAID: non-steroidal anti-inflammatory drugs.
Table 7 Incidence of AKI on day 7 and at the EOT related
to quartiles of Cmin values at steady state
Cmin (mg/dL)
≤ 0.56 0.57-1.04 1.05-2.2 > 2.2
Nephrotoxicity on day 7 1 (4) 0 (0) 8 (32) 17 (65.4)
Cmin (mg/dL)
≤ 0.56 0.57-1.04 1.05-2.2 > 2.2
Nephrotoxicity at the EOT 5 (20) 10 (38.5) 13 (52) 22 (84.6)
Data are n (%) of patients in each concentration category.
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several samples from patients that were not in the ICU.
CMS plasma concentrations were not determined. CMS
is mainly cleared renally and for this reason creatinine
clearance reductions may produce CMS accumulation
[23]. Consequently, a larger proportion of CMS is
converted to colistin, and brings about an increase of
the colistin plasma levels in patients with creatinine
clearance reductions. The possible association between
CMS concentrations and AKI should be assessed in fur-
ther studies. Finally, the severity of disease at the time of
the first CMS dose was stratified in all included patients
according to the Acute Physiology and the Chronic
Health Evaluation (APACHE) II, despite the fact that this
score has only been validated in ICU patients.
Conclusions
To our knowledge, the present study is the first to
demonstrate that Cmin is an independent risk factor for
colistin-associated AKI. In fact, Cmin was identified as
the only predictor for AKI after a week of CMS treat-
ment and also a potent risk factor for renal toxicity at
the EOT. Consequently, monitoring plasma concentra-
tions of colistin may be a useful strategy for the predic-
tion and prevention of AKI in patients undergoing
CMS therapy.
This study also raises new challenges. According to the
observations by other authors [24,31] and in the present
study, even at steady state, plasma concentrations were
below MIC breakpoints for most of the MDR-GNB causing
infections. This shows that further investigations are
needed to define the optimal colistin plasma concentrations
and, consequently, the optimum-dosing regimen. In this
scenario, the study results suggest that physicians should be
cautious about using colistin and that monitoring colistin
plasma concentrations is valuable for preventing colistin-
associated nephrotoxicity.
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